Aug 07,2024

Medtronic announces FDA approval of Simplera CGM

Medtronic announced FDA approval for its Simplera continuous glucose monitor (CGM), its first disposable, all-in-one CGM that's half the size of previous models, designed for easier insertion and wear without overtape. The Simplera™ platform includes the Simplera CGM and the Simplera Sync™ sensor, which integrates with Medtronic's MiniMed 780G system and will eventually work with the InPen™ smart insulin pen.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 25,2024

Investment firm Altaris acquires digital health company Sharecare for $518M

Sharecare, a publicly traded digital health company known for its patient engagement and health navigation platform, has agreed to be acquired by healthcare investment firm Altaris in a $518 million deal, which will take the company private. Sharecare provides virtual healthcare navigation, patient education, mobile apps, and digital therapeutics for various health issues. Under the agreement, Sharecare stockholders will receive $1.43 per share, an 85% premium over the pre-announcement stock price.

COLLABORATION MERGERS & ACQUISITION

#product & service

View Analyst & Ambassador Comments
Go to original news
Jul 17,2024

Fitterfly, Google Cloud launch meal tracking app using computer vision

India-based digital therapeutics company Fitterfly has launched "Fitterfly Klik," an AI-powered feature developed in partnership with Google Cloud, to help individuals with diabetes and other noncommunicable diseases track their meals using computer vision. By taking or uploading a photo of their meal, users can receive an analysis of the food, including portion size, calorie count, and nutrient distribution. The AI, powered by Google's Vertex AI platform, can recognize over 37,000 Indian and international dishes.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 07,2024

ABBOTT ENTERS GLOBAL PARTNERSHIP TO CONNECT ITS WORLD-LEADING CONTINUOUS GLUCOSE MONITORING SYSTEM WITH MEDTRONIC'S INSULIN DELIVERY DEVICES

Abbott announced a global partnership with Medtronic to develop an integrated continuous glucose monitoring (CGM) system using Abbott's FreeStyle Libre technology. This system will work exclusively with Medtronic's automated insulin delivery (AID) and smart insulin pen systems, enabling automatic insulin adjustments to maintain glucose levels. Financial details and commercial availability were not disclosed.

COLLABORATION PARTNERSHIP

#connected device

#closed loop

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Jul 30,2024

Fitterfly Healthtech Partners with Ascensia Diabetes Care to Improve Diabetes Management

Fitterfly, an Indian diabetes management company, has partnered with Ascensia Diabetes Care to enhance diabetes management through the integration of Ascensia's Bluetooth-enabled Contour Plus Elite glucometer into Fitterfly's Diabetes Program Kits and app. This collaboration aims to improve regular glucose monitoring among program members, facilitated by expert coaching from Fitterfly.

COLLABORATION PARTNERSHIP

#connected device

#bgm

#coaching

View Analyst & Ambassador Comments
Go to original news
Aug 02,2024

Ypsomed and MTD complete the sale of the pen needle and BGM business

Ypsomed and Medical Technology and Devices S.p.A. (MTD) have completed the sale of Ypsomed's pen needle and blood glucose monitoring (BGM) systems business. This transaction, initially announced on March 27, 2024, enables Ypsomed to concentrate on its mylife Loop insulin pump solution. MTD's acquisition, described as transformative by CEO Charles Bouaziz, accelerates their growth and positions them as the second-largest pen needle producer globally. During the transition, Ypsomed will continue producing pen needles as a contract manufacturer until mid-2025.

COLLABORATION MERGERS & ACQUISITION

#product & service

#insulin pump

#bgm

View Analyst & Ambassador Comments
Go to original news
Aug 02,2024

Trinity Biotech Provides Preliminary Second Quarter 2024 Update and Enters into UK Distribution Agreement with MedScience

Trinity Biotech plc, a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, announced preliminary second quarter 2024 revenues of $15.5-$16.0 million, reflecting significant year-over-year growth from $13.9 million in Q2 2023. The company reiterates its financial guidance aiming for $20 million in annualized run-rate EBITDASO on $75 million in revenues by Q2 2025. Additionally, Trinity Biotech has entered into a UK distribution agreement with MedScience, effective August 1, 2024, covering clinical chemistry, infectious disease, and autoimmune products. This partnership aims to enhance Trinity's presence in the UK market. Full second quarter earnings and updates on their business activities will be reported in mid-August 2024.

View Analyst & Ambassador Comments
Go to original news
Aug 06,2024

Omada Health adds Sachin Jain, M.D., MBA, Julie Klapstein and Adam Stavisky to Board of Directors

Omada Health, a virtual-first healthcare provider, has announced the addition of three new members to its Board of Directors: Sachin Jain, M.D., MBA, Julie Klapstein, and Adam Stavisky. These industry veterans bring extensive clinical and commercial expertise to the board. CEO and Co-Founder Sean Duffy highlighted their experience and vision for transforming healthcare models, particularly in chronic care and emerging technologies like AI and GLP-1s.

View Analyst & Ambassador Comments
Go to original news
Jun 24,2024

Trinity Biotech to Begin European Pre-Pivotal Trial to Optimize its CGM Sensor

Trinity Biotech has announced progress on its next-generation continuous glucose monitoring (CGM) solution, following its acquisition of CGM technology earlier this year. The company has received regulatory approval to start a European pre-pivotal trial, which will assess the enhanced performance of the CGM device. This trial, expected to finish by the end of July, will provide data to optimize the device before a larger pivotal trial planned for 2025.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 31,2024

GLUCOTRACK ANNOUNCES NEW FUNDING FOR DEVELOPMENT OF ITS CONTINUOUS BLOOD GLUCOSE MONITOR

Glucotrack, Inc. has secured $4 million in funding from its major shareholder, John Ballantyne, to support its upcoming First in Human clinical trial for its Continuous Blood Glucose Monitor (CBGM) technology. CEO Paul V. Goode noted significant progress in the technology's development and expressed confidence in its potential impact on the diabetes market. Ballantyne praised the company's advancements and leadership, emphasizing the potential for significant clinical and shareholder value.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES